Results 41 to 50 of about 10,088 (191)

Rifaximin Therapy of Irritable Bowel Syndrome

open access: yes, 2012
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology.
Saman Sabounchi   +3 more
core   +1 more source

Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids [PDF]

open access: yes, 2023
BACKGROUND AND AIMS: Recurrent hepatic encephalopathy (HE) is characterized by hyperammonaemia in combination with neuropsychiatric abnormalities and is treated with lactulose and rifaximin.
Beuers, Ulrich   +14 more
core  

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy

open access: yesMedicina
Background and Objectives: This analysis described rifaximin utilization in Italian patients with hepatic encephalopathy (HE). Although rifaximin is effective in preventing HE relapses, therapeutic management and prescriptive attitudes might be improved.
Valentina Perrone   +4 more
doaj   +1 more source

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
The gut microbiota has an important role in the pathogenesis of hepatic encephalopathy(HE). Rifaximin, an intestinal non-absorbable antibacterial agent, is effective in the treatment of HE.
Xiao Yu   +12 more
doaj   +1 more source

Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice

open access: yesFrontiers in Cellular and Infection Microbiology, 2019
Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent ...
Lianjun Yang   +12 more
doaj   +1 more source

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome

open access: yesBMC Gastroenterology, 2020
Background Gut microbiota alterations including small intestinal bacterial overgrowth (SIBO) might play a role in pathogenesis of irritable bowel syndrome (IBS). Rifaximin could effectively and safely improve IBS symptoms.
Xiaojun Zhuang   +3 more
doaj   +1 more source

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication [PDF]

open access: yesThe Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2020
Background/Aims The treatment options for Helicobacter pylori (H. pylori) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are
Hyun Soo Kim   +9 more
doaj   +1 more source

A framework for integrating health‐related social needs education into electronic health record clinical pathways

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Health‐related social needs (HRSN) significantly influence patient outcomes, yet they are rarely integrated into point‐of‐care decision‐making. We developed a process to embed HRSN‐informed and HRSN‐targeted care recommendations directly into three electronic health record‐integrated high‐use clinical pathways—cirrhosis, diabetes, and ...
Karthik Warke Rohatgi   +5 more
wiley   +1 more source

An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin

open access: yesScientific Reports, 2022
Current knowledge suggests that infection by carbapenem-resistant enterobacteria is preceded by gut colonization. It is hypothesized that colonization is eradicated by non-absorbable antibiotics like rifaximin.
Eleni Xenofontos   +8 more
doaj   +1 more source

Biochemical testing and pathology reveal rare cause of pediatric acute liver failure: Hyperornithinemia‐hyperammonemia‐homocitrullinuria syndrome

open access: yesJPGN Reports, EarlyView.
Abstract Hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome is a rare metabolic condition that can cause lethargy, ataxia, tachypnea, nausea, vomiting, seizures, coma, and acute liver failure. We present a 26‐month‐old female with acute liver failure who was diagnosed with HHH 1 week after admission. Histology revealed an acute hepatitic
Tierra L. Mosher   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy